Condition: Solid Tumours · Sponsor: AP Biosciences Inc.
A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given safely. Participants will be assigned to one of six cohorts. Each cohort will receive a different dose of the study medication, AP601, based on the body weight. Each cohort will initially enrol 1-3 participants. If no serious side effects are seen in the first participant(s), the next cohort will receive the next dose level.
This description comes directly from the study's public registry record.
Grace Lu · 886-2-2653-2886 · cwlu@apbioinc.com
Always discuss trial participation with your own doctor first.
| Calvary Mater Newcastle | Waratah, New South Wales, Australia | Not Yet Recruiting |
| Pindara Private Hospital | Brisbane, Queensland, Australia | Not Yet Recruiting |
| Epworth HealthCare | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07165067